Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise
Authors:
Open Access
- 14 January 1999
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 79 (3-4) , 538-544
Abstract
The assessment of symptom palliation is an essential component of many treatment comparisons in clinical trials, yet an extensive literature search revealed no consensus as to its precise definition, which could embrace relief of symptoms, time to their onset, duration, degree, as well as symptom control and prevention. In an attempt to assess the importance of these aspects and to compare different methods of analysis, we used one symptom (cough) from a patient self-assessment questionnaire (the Rotterdam Symptom Checklist) in a large (>300 patient) multicentre randomized clinical trial (conducted by the Medical Research Council Lung Cancer Working Party) of palliative chemotherapy in small-cell lung cancer. The regimens compared were a two-drug regimen (2D) and a four-drug regimen (4D). No differences were seen between the regimens in time of onset of palliation or its duration. The degree of palliation was strongly related to the initial severity: 90% of the patients with moderate or severe cough at baseline reported improvement, compared with only 53% of those with mild cough. Analyses using different landmark time points gave conflicting results: the 4D regimen was superior at 1 month and at 3 months, whereas at 2 months the 2D regimen appeared superior. When improvement at any time up to 3 months was considered, the 4D regimen showed a significant benefit (4D 79%, 2D 60%, P = 0.02). These findings emphasize the need for caution in interpreting results, and the importance of working towards a standard definition of symptom palliation. The current lack of specified criteria makes analysis and interpretation of trial results difficult, and comparison across trials impossible. A standard definition of palliation for use in the analysis of clinical trials data is proposed, which takes into account aspects of onset, duration and degree of palliation, and symptom improvement, control and prevention.Keywords
This publication has 33 references indexed in Scilit:
- Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracilEuropean Journal of Cancer, 1997
- Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance statusClinical Oncology, 1996
- Intraluminal brachytherapy using the high dose rate microSelectron in the palliation of carcinoma of the oesophagusClinical Oncology, 1995
- Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified?Lung Cancer, 1994
- Forthcoming EventsEuropean Journal of Cancer Care, 1994
- Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group.Thorax, 1993
- Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of lifeEuropean Journal of Cancer, 1992
- A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesisEuropean Journal of Cancer, 1992
- A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to boneEuropean Journal of Cancer and Clinical Oncology, 1991
- Prospective randomised trial of laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia.Gut, 1990